Oruka Therapeutics, Inc. Common Stock
Here’s whether Oruka Therapeutics, Inc. Common Stock (ORKA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+17.40% over 10 days); RSI 52 — healthy momentum range; strong 1-year return of +520.2%; 3-month momentum positive (+82.5%); rising volume confirms the move (1.71x 30d avg). Currently 31.2% off its 52-week high. Score: +8/7.
ORKA is in a confirmed uptrend, trading above both its 50-day ($49.75) and 200-day ($30.66) moving averages. An RSI of 51.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +520.2% compares to +27.9% for SPY (beat the market by 492.3%). The current 31.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.